Orig3n has raised $20 million in a recent round of private financing. The Boston-based firm offers direct-to-consumer genetic tests and is developing regenerative medicine projects. A spokesperson said Orig3n will use proceeds from the financing to expand its research into cell therapies. Hatteras Venture Partners led the round of financing, which included previous investors LabCorp, Syno Capital, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners, and 180 Degree Capital, and new investor Spectrum Health Ventures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.